Company: BLNE
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001641172-25-004793
Chunk: 220

Company: Beeline Holdings, Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 220
---
 result of its merger with Old Beeline, there can be no assurances that
we will not violate such rule again in the future. The second deficiency relates to the minimum bid price being below $1.00. While we
effected a reverse stock split at a ratio of 1-for-10 to increase our stock price in March 2025, there are no assurances that this reverse
split and other events will allow us to maintain the minimum bid price required to comply with Nasdaq’s rules. In addition, a new
Nasdaq rule recently took effect which precludes listed issuers that have already effected a reverse split within the prior one-year period
from receiving a grace period for bid price deficiencies. Prior to the rule taking effect, such issuers would receive the general 180-day
grace period to cure a bid price deficiency (plus the potential for an additional 180-day extension at the end of such initial grace period)
to regain compliance with the minimum bid price requirement. Therefore, if the trading price of our common stock is below $1.00 for 30
consecutive trading days, before March 12, 2026, it would result in us receiving an immediate delist notice from Nasdaq without any 180-day
grace period to regain compliance. Additionally, the new Nasdaq rule also provides that a reverse split cannot be used to cure a bid price
deficiency if there have been two or more reverse splits within a two-year period and the combined ratios of such reverse splits are 250:1
or greater. These new rules will make it difficult to cure a bid price deficiency if the timing and circumstances are such that we cannot
obtain a grace period or otherwise take the necessary actions and obtain the required approvals to effect a reverse split before a bid
price deficiency occurs. If the Company’s common stock is delisted it would negatively impact the Company’s ability to raise
capital and negatively impact our stockholders’ ability to trade their common stock.

The sale or issuance of our
Common Stock under the ELOC and other financing transactions we may undertake will create dilution to our other shareholders and could
cause the price of our Common Stock to fall, and such transactions may not be effective in raising sufficient capital as and when needed.

Pursuant to the ELOC Agreement, as amended,
we may sell up to $10.0 million of our Common Stock to the purchaser thereunder. The shares of Common Stock that may be sold pursuant to
the ELOC Agreement may